Shares of Cortexyme, Inc. (NASDAQ:CRTX - Get Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.27 and traded as high as $1.69. Cortexyme shares last traded at $1.67, with a volume of 132,622 shares changing hands.
Cortexyme Stock Performance
The company has a market capitalization of $43.12 million, a P/E ratio of -0.48 and a beta of 1.40. The stock's fifty day moving average price is $1.79 and its 200-day moving average price is $1.29.
About Cortexyme
(
Get Free Report)
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Read More
Before you consider Cortexyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cortexyme wasn't on the list.
While Cortexyme currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
